ATE482214T1 - Aspartylproteasehemmer - Google Patents

Aspartylproteasehemmer

Info

Publication number
ATE482214T1
ATE482214T1 AT06784753T AT06784753T ATE482214T1 AT E482214 T1 ATE482214 T1 AT E482214T1 AT 06784753 T AT06784753 T AT 06784753T AT 06784753 T AT06784753 T AT 06784753T AT E482214 T1 ATE482214 T1 AT E482214T1
Authority
AT
Austria
Prior art keywords
protease inhibitors
aspartyl protease
aspartyl
inhibitors
protease
Prior art date
Application number
AT06784753T
Other languages
English (en)
Inventor
Zhaoning Zhu
Brian Mckittrick
Andrew Stamford
Ying Huang
Elizabeth Smith
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Application granted granted Critical
Publication of ATE482214T1 publication Critical patent/ATE482214T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cardiology (AREA)
  • AIDS & HIV (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT06784753T 2005-06-14 2006-06-12 Aspartylproteasehemmer ATE482214T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US69032605P 2005-06-14 2005-06-14
PCT/US2006/022698 WO2006138192A1 (en) 2005-06-14 2006-06-12 Aspartyl protease inhibitors

Publications (1)

Publication Number Publication Date
ATE482214T1 true ATE482214T1 (de) 2010-10-15

Family

ID=37074234

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06784753T ATE482214T1 (de) 2005-06-14 2006-06-12 Aspartylproteasehemmer

Country Status (17)

Country Link
US (1) US7759354B2 (de)
EP (1) EP1896477B1 (de)
JP (1) JP2008543840A (de)
KR (1) KR20080031189A (de)
CN (1) CN101198609A (de)
AR (1) AR054620A1 (de)
AT (1) ATE482214T1 (de)
AU (1) AU2006259675A1 (de)
CA (1) CA2610812A1 (de)
DE (1) DE602006017073D1 (de)
ES (1) ES2350854T3 (de)
IL (1) IL187623A0 (de)
MX (1) MX2007016175A (de)
PE (1) PE20070018A1 (de)
TW (1) TW200716644A (de)
WO (1) WO2006138192A1 (de)
ZA (1) ZA200710337B (de)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7700603B2 (en) 2003-12-15 2010-04-20 Schering Corporation Heterocyclic aspartyl protease inhibitors
US7763609B2 (en) 2003-12-15 2010-07-27 Schering Corporation Heterocyclic aspartyl protease inhibitors
US7592348B2 (en) 2003-12-15 2009-09-22 Schering Corporation Heterocyclic aspartyl protease inhibitors
WO2006138264A2 (en) 2005-06-14 2006-12-28 Schering Corporation Aspartyl protease inhibitors
ATE482214T1 (de) 2005-06-14 2010-10-15 Schering Corp Aspartylproteasehemmer
ES2537898T3 (es) 2005-10-25 2015-06-15 Shionogi & Co., Ltd. Derivados de aminotiazolidina y aminotetrahidrotiazepina como inhibidores de BACE 1
CA2653650A1 (en) 2006-06-12 2007-12-21 Schering Corporation Heterocyclic aspartyl protease inhibitors
MX2009006228A (es) 2006-12-12 2009-06-22 Schering Corp Inhibidores de aspartil proteasa.
CN101631779A (zh) * 2006-12-12 2010-01-20 先灵公司 含有三环系统的天冬氨酰蛋白酶抑制剂
AU2008245082B8 (en) 2007-04-24 2012-09-13 Shionogi & Co., Ltd. Aminodihydrothiazine derivatives substituted with a cyclic group
EP2151435A4 (de) 2007-04-24 2011-09-14 Shionogi & Co Pharmazeutische zusammensetzung zur behandlung von morbus alzheimer
CN101848897A (zh) 2007-09-06 2010-09-29 先灵公司 γ分泌酶调节剂
US8487099B2 (en) 2007-11-05 2013-07-16 Merck Sharp & Dohme Corp. Gamma secretase modulators
WO2009076352A1 (en) 2007-12-11 2009-06-18 Schering Corporation Gamma secretase modulators
AU2009239536C1 (en) 2008-04-22 2012-12-13 Merck Sharp & Dohme Corp. Phenyl-substituted 2-imino-3-methyl pyrrolo pyrimidinone compounds as BACE-1 inhibitors, compositions, and their use
US8637504B2 (en) 2008-06-13 2014-01-28 Shionogi & Co., Ltd. Sulfur-containing heterocyclic derivative having beta secretase inhibitory activity
US8450308B2 (en) * 2008-08-19 2013-05-28 Vitae Pharmaceuticals, Inc. Inhibitors of beta-secretase
WO2010047372A1 (ja) 2008-10-22 2010-04-29 塩野義製薬株式会社 Ｂａｃｅ１阻害活性を有する２－アミノピリミジン－４－オンおよび２－アミノピリジン誘導体
JP5503663B2 (ja) 2008-11-13 2014-05-28 メルク・シャープ・アンド・ドーム・コーポレーション ガンマセクレターゼモジュレータ
EP2379566A2 (de) 2008-12-22 2011-10-26 Schering Corporation Modulatoren von gamma-sekretase
AU2009330233A1 (en) 2008-12-22 2011-07-07 Merck Sharp & Dohme Corp. Gamma secretase modulators
WO2010105179A2 (en) 2009-03-13 2010-09-16 Vitae Pharmaceuticals, Inc. Inhibitors of beta-secretase
EP2443118A1 (de) 2009-06-16 2012-04-25 Schering Corporation Gammasekretasemodulatoren
US20120245158A1 (en) 2009-06-16 2012-09-27 Xianhai Huang Gamma secretase modulators
WO2010147969A2 (en) 2009-06-16 2010-12-23 Schering Corporation Gamma secretase modulators
UA108363C2 (uk) 2009-10-08 2015-04-27 Похідні імінотіадіазиндіоксиду як інгібітори bace, композиція на їх основі і їх застосування
WO2011044185A2 (en) 2009-10-08 2011-04-14 Schering Corporation Pentafluorosulfur imino heterocyclic compounds as bace-1 inhibitors, compositions, and their use
WO2011044187A1 (en) 2009-10-08 2011-04-14 Schering Corporation Iminothiadiazine dioxide compounds as bace inhibitors, compositions, and their use
WO2011044184A1 (en) 2009-10-08 2011-04-14 Schering Corporation Pentafluorosulfur imino heterocyclic compounds as bace-1 inhibitors, compositions, and their use
RU2012129168A (ru) 2009-12-11 2014-01-20 Сионоги Энд Ко. Лтд. Производные оксазина
JP5828848B2 (ja) 2010-02-24 2015-12-09 ヴァイティー ファーマシューティカルズ，インコーポレイテッド ベータセクレターゼインヒビター
US9018219B2 (en) 2010-10-29 2015-04-28 Shionogi & Co., Ltd. Fused aminodihydropyrimidine derivative
CA2816285A1 (en) 2010-10-29 2012-05-03 Shionogi & Co., Ltd. Naphthyridine derivative
WO2012138734A1 (en) 2011-04-07 2012-10-11 Merck Sharp & Dohme Corp. C5-c6 oxacyclic-fused thiadiazine dioxide compounds as bace inhibitors, compositions, and their use
EP2694521B1 (de) 2011-04-07 2015-11-25 Merck Sharp & Dohme Corp. Pyrrolidin-kondensierte thiadiazindioxidverbindungen als bace-hemmer, zusammensetzungen daraus und ihre verwendung
WO2012147763A1 (ja) 2011-04-26 2012-11-01 塩野義製薬株式会社 オキサジン誘導体およびそれを含有するｂａｃｅ１阻害剤
RU2014111055A (ru) 2011-08-22 2015-09-27 Мерк Шарп И Доум Корп. 2-спирозамещенные иминотиазины и их моно- и диоксиды в качестве ингибиторов bace, композиции и их применение
TWI557112B (zh) 2012-03-05 2016-11-11 百靈佳殷格翰國際股份有限公司 β－分泌酶抑制劑
ES2745539T3 (es) 2012-03-19 2020-03-02 Buck Inst Res Aging Inhibidores de BACE específicos de APP (ASBI) y uso de los mismos
TW201422592A (zh) 2012-08-27 2014-06-16 Boehringer Ingelheim Int β－分泌酶抑制劑
WO2014052398A1 (en) 2012-09-28 2014-04-03 Vitae Pharmaceuticals, Inc. Inhibitor of beta-secretase
EP2908825B1 (de) 2012-10-17 2018-04-18 Merck Sharp & Dohme Corp. Tricyclische substituierte thiadiazindioxidverbindungen als bace-hemmer, zusammensetzungen und deren verwendung
WO2014062553A1 (en) 2012-10-17 2014-04-24 Merck Sharp & Dohme Corp. Tricyclic substituted thiadiazine dioxide compounds as bace inhibitors, compositions, and their use
JP2016501827A (ja) 2012-10-24 2016-01-21 塩野義製薬株式会社 Ｂａｃｅ１阻害作用を有するジヒドロオキサジンまたはオキサゼピン誘導体
EP3653609B1 (de) 2013-02-12 2024-04-03 Buck Institute for Research on Aging Hydantoine als modulatoren von bace-vermittelter app-verarbeitung
WO2014127881A1 (de) 2013-02-25 2014-08-28 Merck Patent Gmbh 2-amino-3,4-dihydrc-chinazolin derivate und ihre verwendung als cathepsin d inhibitoren
US11766435B2 (en) 2016-02-18 2023-09-26 Merck Sharp & Dohme Llc N3-substituted iminopyrimidinones as antimalarial agents

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3865836A (en) * 1972-12-08 1975-02-11 Janssen Pharmaceutica Nv Bicyclic imidazoles
JPS5946518B2 (ja) * 1976-12-23 1984-11-13 第一製薬株式会社 ２，２−又は３，３−ジ置換−イミダゾ〔１，２−ａ〕〔１，３〕ジアザシクロアルカン類
GB8312892D0 (en) * 1983-05-11 1983-06-15 Raychem Ltd Electrical insulator
JPS60173546A (ja) * 1984-02-20 1985-09-06 Fuji Photo Film Co Ltd ハロゲン化銀写真感光材料の現像処理方法
IL102764A0 (en) * 1991-08-16 1993-01-31 Merck & Co Inc Quinazoline derivatives,and pharmaceutical compositions containing them
WO1993004047A1 (en) * 1991-08-16 1993-03-04 Merck & Co., Inc. Quinazoline derivatives as inhibitors of hiv reverse transcriptase
US5958920A (en) * 1994-12-02 1999-09-28 The United States Of America As Represented By The Department Of Health And Human Services Aralkyl diazabicycloalkane derivatives for CNS disorders
CA2260216A1 (en) * 1996-07-15 1998-01-22 Bristol-Myers Squibb Company Thiadioxobenzodiazepine inhibitors of farnesyl protein transferase
FR2756282B1 (fr) * 1996-11-22 1998-12-31 Elf Aquitaine Procede de synthese d'esters de l'acide mercapto-3-propionique
WO1999050249A2 (en) * 1998-04-01 1999-10-07 Du Pont Pharmaceuticals Company Pyrimidines and triazines as integrin antagonists
EP1340761A1 (de) * 2002-02-28 2003-09-03 Sanofi-Synthelabo Substituierte 2-Pyridinyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-on und 7-Pyridinyl-2,3-dihydroimidazo[1,2-a]pyrimidin-5(1H)onderivate
WO2003027115A1 (en) * 2001-09-21 2003-04-03 Sanofi-Synthelabo Substituted 2-pyrimidinyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one and 7-pyrimidinyl-2,3-dihydroimidazo[1,2-a]pyrimidin-5(1h)one derivatives for neurodegenerative disorders
EP1340760A1 (de) 2002-02-28 2003-09-03 Sanofi-Synthelabo Substituierte 2-Pyrimidinyl-6,7,8,9-tetrahydro[1,2-a]pyrimidin-4-on und 7-Pyrimidinyl-2,3-dihydroimidazo[1,2-a]pyrimidin-5(1H)onderivate
EP1295885A1 (de) 2001-09-21 2003-03-26 Sanofi-Synthelabo Substituierte 2-pyridinyl-6,7,8,9-tetrahydropyrimido(1,2-a)pyrimidin-4-on- und 7-pyridinyl-2,3-dihydroimidazo(1,2-a)pyrimidin-5(1H)onderivate
CN1863770B (zh) 2003-08-08 2011-05-25 先灵公司 具有杂环取代基的环胺base-1抑制剂
CA2534950A1 (en) * 2003-08-08 2005-02-24 Schering Corporation Cyclic amine bace-1 inhibitors having a benzamide substituent
EP1701772A4 (de) 2003-11-21 2012-03-28 Univ Johns Hopkins Biomolekülpartitionsmotive und verwendungen davon
US7700603B2 (en) * 2003-12-15 2010-04-20 Schering Corporation Heterocyclic aspartyl protease inhibitors
US7763609B2 (en) * 2003-12-15 2010-07-27 Schering Corporation Heterocyclic aspartyl protease inhibitors
US7592348B2 (en) * 2003-12-15 2009-09-22 Schering Corporation Heterocyclic aspartyl protease inhibitors
CA2548388A1 (en) 2003-12-15 2005-06-30 Schering Corporation Heterocyclic aspartyl protease inhibitors
JPWO2005073365A1 (ja) 2004-01-29 2007-09-13 株式会社 ジャパン・ティッシュ・エンジニアリング 移植用細胞の処理方法、細胞懸濁液、移植用補綴物、および損傷部位の治療方法
DE102004007076A1 (de) * 2004-02-13 2005-08-25 Bayer Cropscience Ag Imidazolopyrimidine
CA2579724A1 (en) * 2004-06-16 2006-01-26 Wyeth Amino-5,5-diphenylimidazolone derivatives for the inhibition of beta-secretase
CA2578600A1 (en) * 2004-06-16 2006-01-26 Wyeth Diphenylimidazopyrimidine and -imidazole amines as inhibitors of b-secretase
JP2008507538A (ja) * 2004-07-22 2008-03-13 シェーリング　コーポレイション 置換アミドβセクレターゼインヒビター
CA2575340A1 (en) 2004-07-28 2006-02-09 Schering Corporation Macrocyclic beta-secretase inhibitors
WO2006044497A2 (en) 2004-10-13 2006-04-27 Merck & Co., Inc. Spiropiperidine compounds useful as beta-secretase inhibitors for the treatment of alzhermer’s disease
US20090221579A1 (en) 2004-10-15 2009-09-03 Jeffrey Scott Albert Substituted Amino-Compounds and Uses Thereof
WO2006089122A2 (en) * 2005-02-18 2006-08-24 North Carolina State University De novo synthesis of bacteriochlorins
ATE482214T1 (de) 2005-06-14 2010-10-15 Schering Corp Aspartylproteasehemmer
ATE489370T1 (de) * 2005-06-14 2010-12-15 Schering Corp Herstellung und verwendung von verbindungen als aspartylproteasehemmer
WO2006138264A2 (en) * 2005-06-14 2006-12-28 Schering Corporation Aspartyl protease inhibitors
EP1896406A2 (de) * 2005-06-14 2008-03-12 Shering Corporation Herstellung und verwendung von verbindungen als proteaseinhibitoren
CA2609562A1 (en) 2005-06-14 2006-12-28 Schering Corporation Macrocyclic heterocyclic aspartyl protease inhibitors
US7759353B2 (en) 2005-06-14 2010-07-20 Schering Corporation Substituted spiro iminopyrimidinones as aspartyl protease inhibitors, compositions, and methods of treatment
US8722708B2 (en) * 2005-06-14 2014-05-13 Merck Sharp & Dohme Inc. Substituted isoindolines as aspartyl protease inhibitors
EP1928237A4 (de) * 2005-09-02 2011-03-09 Abbott Lab Neue heterocyclen auf imidazo-basis
CN101296926A (zh) 2005-10-27 2008-10-29 先灵公司 天冬氨酰蛋白酶抑制剂
CN101351460A (zh) * 2005-10-31 2009-01-21 先灵公司 天冬氨酰蛋白酶抑制剂
WO2007084450A2 (en) 2006-01-18 2007-07-26 Schering Corporation Cannibinoid receptor modulators
CA2653650A1 (en) * 2006-06-12 2007-12-21 Schering Corporation Heterocyclic aspartyl protease inhibitors
EP2086644A2 (de) 2006-11-17 2009-08-12 Schering Corporation Kombination aus einem hemmer der dna-polymerase-alpha und einem hemmer der checkpointkinase zur behandlung von proliferativen erkrankungen
MX2009006228A (es) 2006-12-12 2009-06-22 Schering Corp Inhibidores de aspartil proteasa.
CN101631779A (zh) 2006-12-12 2010-01-20 先灵公司 含有三环系统的天冬氨酰蛋白酶抑制剂

Also Published As

Publication number Publication date
AU2006259675A1 (en) 2006-12-28
TW200716644A (en) 2007-05-01
WO2006138192A1 (en) 2006-12-28
CA2610812A1 (en) 2006-12-28
ZA200710337B (en) 2008-12-31
MX2007016175A (es) 2008-03-07
ES2350854T3 (es) 2011-01-27
DE602006017073D1 (en) 2010-11-04
PE20070018A1 (es) 2007-03-08
JP2008543840A (ja) 2008-12-04
HK1109151A1 (en) 2008-05-30
US20060281730A1 (en) 2006-12-14
EP1896477A1 (de) 2008-03-12
KR20080031189A (ko) 2008-04-08
IL187623A0 (en) 2008-03-20
CN101198609A (zh) 2008-06-11
US7759354B2 (en) 2010-07-20
AR054620A1 (es) 2007-07-04
EP1896477B1 (de) 2010-09-22

Similar Documents

Publication Publication Date Title
ATE478070T1 (de) Heterozyklische aspartyl-proteasehemmer
ATE530554T1 (de) Serinprotease-hemmer
ATE439835T1 (de) Heterozyklische aspartyl-proteasehemmer
IL187815A0 (en) Aspartyl protease inhibitors
IL187814A0 (en) Aspartyl protease inhibitors
IL187623A0 (en) Aspartyl protease inhibitors
LTPA2017010I1 (lt) Proteazomos inhibitoriai
DK1699455T3 (da) Heterocykliske aspartylproteasehæmmere
BRPI0807547A2 (pt) Inibidores de aspartil protease hetercíclicos
IL195592A0 (en) Heterocyclic aspartyl protease inhibitors
EP1981519A4 (de) Proteasehemmung
NO20076678L (no) Glutamataggrekanaseinhibitorer
DK1924593T3 (da) HCV NS3-proteaseinhibitorer
NO2018013I1 (no) Opikapon
ATE538092T1 (de) Asparaginsäureproteaseinhibitoren
ATE461200T1 (de) Inhibitoren von cysteinprotease
DK2032535T3 (da) Spiro-cycliske nitriler som protease-inhibitorer
DK1817276T3 (da) Cathepsin cysteine protease inhibitors
EP1921078A4 (de) Multikinaseinhibitor
DK1865940T3 (da) Alfaketoamidforbindelser som cysteinproteasehæmmere
GB0513841D0 (en) Cysteine protease inhibitors
ATE429417T1 (de) Hiv-protease-inhibitoren
ATE418545T1 (de) Nnrt-inhibitoren
ZA200804025B (en) Aspartic protease inhibitors
GB0513840D0 (en) Cysteine protease inhibitors

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties